JBJahangeer Basha

Jahangeer Basha

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jahangeer Basha has a total of 89 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Correction: Endoscopic ultrasound-guided transpapillary versus transluminal biliary stenting: randomized comparison of long-term stent patency

    by Vinay Dhir, Vivek Kumar Singh, Sundeep Lakhtakia, Rajesh Puri, Praveer Rai, Nonthalee Pausawasdi, Ryosuke Tonozuka, Jahangeer Basha, Varayu Prachayakul, Abhishek Kathuria, et al.

    10.1055/a-2721-6292 In the above-mentioned article the values for “Technical success” and “Clinical success” in Table 3 have been corrected. This was corrected in the online version on December 19, 2025. Article published online: 17 December 2025 © 2025. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

  • Endoscopic ultrasound-guided transpapillary versus transluminal biliary stenting: randomized comparison of long-term stent patency

    by Vinay Dhir, Vivek Kumar Singh, Sundeep Lakhtakia, Rajesh Puri, Praveer Rai, Nonthalee Pausawasdi, Ryosuke Tonozuka, Jahangeer Basha, Varayu Prachayakul, Abhishek Kathuria, et al.

    Endoscopic ultrasound-guided biliary drainage (EUS-BD) may be transluminal (choledochoduodenostomy [CDS] and hepaticogastrostomy [HGS]) or transpapillary via an antegrade approach; it is unclear which route is preferred. We conducted a multicenter randomized study comparing the two routes. In this open-label randomized study from five tertiary centers, patients with unresectable malignant biliary obstruction and failed endoscopic retrograde cholangiopancreatography were randomized to either EUS-CDS/HGS or transpapillary stenting. The primary outcome was stent patency (recurrent biliary obstruction), assessed at 1, 3, 6, and 12 months. Analysis was on a per-protocol basis. 120 patients (67 males) were recruited (November 2021 to March 2024), with 60 patients in each arm (24 CDS, 36 HGS). The median time to recurrent biliary obstruction was 294 days (95%CI 257.95–330.04) in the transpapillary group and 219 days (95%CI 122.45–315.54) in the transluminal group (P = 0.03). At 3 months, 11/54 stents (20.4%) were blocked in the transluminal group versus 3/52 (5.8%) in the transpapillary group (odds ratio [OR] 0.24, 95%CI 0.06–0.91; P = 0.04). At 6 months, 21/54 stents (38.9%) were blocked in the transluminal group versus 11/52 (21.2%) in the transpapillary group (OR 0.42, 95%CI 0.18–0.99; P = 0.04). There were 13 (21.7%) adverse events in the transluminal group (one death), and 8 (13.3%) in the transpapillary group (OR 0.57, 95%CI 0.21–1.46; P = 0.33). Transpapillary EUS-BD achieved longer stent patency and a lower rate of recurrent biliary obstruction at 3 and 6 months compared with the transluminal route.


  • Top Cited Papers
    Open Access

    Endoscopic or surgical gastroenterostomy for malignant gastric outlet obstruction: a randomised trial

    by Ji Young Bang, Rajesh Puri, Sundeep Lakhtakia, Shyam Thakkar, Irving Waxman, Imran Siddiqui, Kristen Arnold, Adarsh Chaudhary, Shubham Mehta, Amanjeet Singh, et al.

    Background Although surgical gastrojejunostomy (SGJ) is the standard method for palliation of gastric outlet obstruction (GOO), an endoscopic method—endoscopic ultrasound-guided gastroenterostomy (EUS-GE)—has been proposed as a novel, less invasive approach. Objective We compared both methods to determine whether clinical outcomes for EUS-GE are superior to surgery. Design We conducted a multicentre, randomised superiority trial of patients with malignant GOO to receive either EUS-GE or SGJ. Primary endpoint was composite measure, consisting of Gastric Outlet Obstruction Scoring System (GOOSS) score of 0 or 1 at hospital discharge, need for reinterventions or supplemental nutrition, or procedure-related adverse events during 6-month follow-up or until death. Secondary endpoints were time to solid diet, length of hospitalisation, health-related quality of life (HRQoL) and treatment costs. Results 74 patients were randomly assigned to EUS-GE (38 patients) or SGJ (36 patients). Primary endpoint occurred in 7.9% of patients who received EUS-GE and 38.9% in SGJ (risk difference −31.0%, 95% CI −47.6% to −11.4%, p=0.002). EUS-GE was associated with more rapid advancement to solid diet (median 2 days (P25–P75, 2–3) vs 5 days (P25–P75, 3.5–9)), shorter hospitalisation (median 3 days (P25–P75, 3–6) vs 9 days (P25–P75, 6–12.5)), better HRQoL for physical (p=0.0016) and social functioning (p=0.011) and lower treatment costs (US$33 934 vs US$51 437, difference −US$17 503 (95% CI −US$27 807 to −US$7920)). Conclusion In this randomised trial, EUS-GE was superior to SGJ with regards to oral intake, need for reinterventions or supplemental nutrition, length of hospitalisation, quality of life and treatment costs. Trial registration number NCT05548114.


  • Can transperineal ultrasound replace endoscopic ultrasound in staging distal ulcerative colitis?

    by Partha Pal, Mohammad Abdul Mateen, Anuradha Sekaran, Kanapuram Pooja, Arzeena Kaleemuddin, Thanmayee Rangineni, Jahangeer Basha, Rajesh Gupta, Manu Tandan, Sundeep Lakhtakia, et al.


  • Biflanged metal stents versus plastic stents for endoscopic ultrasound-guided drainage of walled-off necrosis: a randomized controlled trial

    by Krithi Krishna Koduri, Nitin Jagtap, Sundeep Lakhtakia, Basha Jahangeer, Shujaath Asif, Rupjyoti Talukdar, Guru Trikudanathan, Manu Tandan, Rakesh Kalapala, Zaheer Nabi, et al.

    Background Endoscopic ultrasound (EUS)-guided drainage of walled-off necrosis (WON) using either plastic or metal stents is the mainstay of WON management. Our single-center randomized controlled trial aimed to evaluate the efficacy of biflanged metal stents (BFMSs) and plastic stents for WON drainage. Methods Patients with symptomatic WON amenable to EUS-guided drainage were randomized to receive either BFMSs or plastic stents. The primary outcome was reintervention-free clinical success at 4 weeks. Secondary outcomes were: overall clinical success (complete resolution of symptoms and significant reduction in size of WON [<50% of original size and <5 cm in largest diameter at 4-week follow-up]); number of reinterventions; adverse events (AEs); hospital stay for first admission; and medium-term outcomes at 6 months (recurrence, disconnected pancreatic duct, chronic pancreatitis, and new-onset diabetes mellitus). Results 92 patients were randomized: 46 in each arm. The reintervention-free clinical success rate was significantly higher in the BFMS group on intention-to-treat analysis (67.4% vs. 43.5%; P = 0.02). Overall clinical success at 1 month was similar in both groups. There were significantly fewer reinterventions (median 0 [IQR 0–1] vs. 1 [0–2]; P = 0.03) and shorter hospital stays in the BFMS group (7.0 [SD 3.4] vs. 9.1 [5.5] days; P = 0.04). There were no differences in procedure-related AEs, mortality, or medium-term outcomes. Conclusions BFMSs provide better reintervention-free clinical success at 4 weeks, with shorter hospital stay and without increased risks of AEs, compared with plastic stents for EUS-guided drainage of WON. Medium-term outcomes are however similar for both stent types.


  • Predictors of persistent pain after extracorporeal shockwave lithotripsy for painful chronic calcific pancreatitis

    by Nitish Gurav, Nitin Jagtap, Vinod Koppoju, Kiran Sekhramantri, Shujaath Asif, Manu Tandan, Sundeep Lakhtakia, Rakesh Kalapala, Mohan Ramchandani, Rupjyoti Talukdar, et al.

    Background Extracorporeal shockwave lithotripsy (ESWL) and/or endoscopic retrograde cholangiopancreatography (ERCP) are recommended as first-line therapy for painful uncomplicated chronic pancreatitis with obstructed main pancreatic duct (MPD) in the pancreas head/body. However, predictors of pain relief after ESWL are unknown. We evaluated independent predictors of persistent pain in patients who underwent ESWL for chronic pancreatitis. Methods 640 consecutive adult patients with chronic pancreatitis, who underwent successful ESWL with ERCP and pancreatic duct (PD) stent placement, were followed for 12 months. The pain was assessed at baseline and at 12 months using the Izbicki Pain Score, with a score decrease of >50% considered pain relief. Independent predictors of pain relief were derived from logistic regression analysis. Results Of 640 patients (mean age 36.71 [SD 12.19] years; 60.5% men), 436 (68.1%) had pain relief and 204 (31.9%) had persistent pain. On univariate analysis, older age, male sex, alcohol and tobacco intake, longer duration of symptoms, dilated MPD and MPD stricture were associated with persistent pain at 12 months (P<0.05). Consumption of alcohol (odds ratio [OR] 1.93, 95%CI 1.26–2.97), tobacco (OR 4.09, 95%CI 2.43–6.90), duration of symptoms (OR 1.02, 95%CI 1.01–1.04), MPD size (OR 1.22, 95%CI 1.11–1.33), and MPD stricture (OR 8.50, 95%CI 5.01–14.42) were independent predictors of persistent pain. Conclusions Alcohol, tobacco, duration of symptoms, MPD size and stricture were independent predictors of persistent pain after successful ESWL. A multidisciplinary team approach that includes behavioral therapy and surgical options should be considered for such patients.


  • EUS-GUIDED LIVER BIOPSY SCORES OVER RADIOLOGY GUIDED PERCUTANEOUS LIVER BIOPSY: A MULTICENTER RANDOMISED CONTROLLED TRIAL

    by J. Samanta, R. Chavan, P. Gupta, L. Chalamarla, J. Dhar, A. Choudhury, I. Panda, S. Mitra, A. Sekharan, A. Das, et al.

    Aims Liver biopsy can be performed by the traditional percutaneous radiology guided route (PC-LB) or under endoscopic ultrasound guidance (EUS-LB) and limited data exist on the comparison between the two and hence this study was planned. Methods This is a parallel-group, single-blinded, randomized controlled trial conducted at two tertiary care centers in India from July 2020-August 2021. Consecutive patients requiring liver biopsy were randomized into either the EUS-LB or the PC-LB arm. Aggregate specimen length, longest specimen length, number of complete portal tracts (CPTs), and diagnostic adequacy were assessed. Post-procedure pain was measured using the visual analog scale (VAS) at 1, 4, and 24 hrs post-procedure. Results A total of 48 patients (30 males; 62.5% with a mean age of 37.25±12.7 years) were randomized into EUS-LB (n=24) and PC-LB (n=24). EUS-LB yielded significantly greater aggregate specimen length (33.5 vs 15.0 mm; p<0.0001) and a higher number of CPTs (17.5 vs. 7.5; p<0.001). The longest length of the specimen was noted in PC-LB arm (10.5 vs. 8.0;p=0.04). Diagnostic adequacy was similar between the two arms. The most common post-procedure side effect was pain. Pain was noted in higher proportion in PC-LB arm (87.5% vs. 16.7%; p<0.001) and had higher analgesic requirement (41.7% vs 4.2%;p=0.004). VAS score was significantly higher in the PC-LB at all the measured time points of 1, 4, and 24 hrs (p<0.001). Conclusions EUS-LB showed significantly better aggregate specimen length and more CPTs compared to PC-LB. Post-procedure pain in the first 24 hrs was significantly greater in the PC-LB arm.(Trial No:CTRI/2020/09/027989) Publication Date: 14 April 2022 (online) © 2022. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

  • Impact of transmural plastic stent on recurrence of pancreatic fluid collection after metal stent removal in disconnected pancreatic duct: a randomized controlled trial

    by Radhika Chavan, Zaheer Nabi, Sundeep Lakhtakia, Rajesh Gupta, Basha Jahangeer, Rupjyoti Talukdar, Aniruddha Pratap Singh, Arun Karyampudi, Raghavendra Yarlagadda, Mohan Ramchandani, et al.

    Background Disconnected pancreatic duct (DPD) after development of walled-off necrosis (WON) predisposes to recurrent (peri)pancreatic fluid collection (PFC). In this randomized controlled trial, we compared plastic stents with no plastic stent after removal of a large-caliber metal stent (LCMS) on incidence of recurrent PFCs in DPD. Methods Consecutive patients with WON who underwent endoscopic ultrasound (EUS)-guided drainage with LCMS between September 2017 and March 2020 were screened for eligibility. At LCMS removal (4 weeks after drainage), patients with DPD were randomized to plastic stent or no stent groups. The primary outcome was incidence of recurrent PFC at 3 months. Secondary outcomes were technical success of plastic stent deployment, adverse events, stent migration, and recurrence of PFC at 6 and 12 months. Results 236 patients with WON underwent EUS-guided drainage using LCMS, and 104 (males 94, median age 34 years (interquartile range [IQR] 26–44.7) with DPD were randomized into stenting (n = 52) and no-stenting (n = 52) groups. Plastic stent deployment was successful in 88.5 %. Migration occurred in 19.2 % at median follow-up of 8 months (IQR 2.5–12). Recurrent PFCs occurred in six patients at 3 months (stent n = 3, no stent n = 3). There was no significant difference in PFC recurrence between the two groups at 3, 6, and 12 months. Reintervention was required in seven patients with recurrent PFCs, with no significant difference between the two groups. Conclusion In patients with WON and DPD, deployment of plastic stents after LCMS removal did not reduce recurrence of PFC.


  • EUS versus MRCP to perform ERCP in patients with intermediate likelihood of choledocholithiasis: a randomised controlled trial

    by Nitin Jagtap, J Kiran Kumar, Radhika Chavan, Jahangeer Basha, Manu Tandan, Sundeep Lakhtakia, Rakesh Kalapala, Zaheer Nabi, Rajesh Gupta, Mohan Ramchandani, et al.

    Objective In patients with an intermediate likelihood of choledocholithiasis, European Society of Gastrointestinal Endoscopy (ESGE) guidelines recommend endoscopic ultrasound (EUS) or magnetic resonance cholangiopancreatography (MRCP) to diagnose choledocholithiasis to make the indication for endoscopic retrograde cholangiopancreatography (ERCP) treatment; there is no randomised control trial to compare both in this setting. Design Patients with suspected choledocholithiasis satisfying ESGE guideline’s intermediate likelihood were screened for this single-centre randomised controlled trial between November 2019 and May 2020. The enrolled patients were randomised to either EUS or MRCP. ERCP was performed in stone positive cases or if clinical suspicion persisted during follow-up. Negative cases underwent a further 6-month clinical follow-up. Main outcome was accuracy (sensitivity/specificity) of both tests to diagnose choledocholithiasis, with ERCP or follow-up as a gold standard. Results Of 266 patients, 224 patients (mean age: 46.77±14.57 years; 50.9 % female) were enrolled; overall prevalence of choledocholithiasis was 49.6%, with a higher frequency in the MRCP group (63/112 vs 46/112 for EUS). Both sensitivity of EUS and MRCP were similarly high (92%–98%), without significant differences between the two groups. The negative predictive value and likelihood ratio + were significantly higher in EUS arm (pConclusion The performance parameters of both EUS and MRCP are comparable for detecting choledocholithiasis in the intermediate-risk group of choledocholithiasis and the choice of a test should be based on local expertise, availability of resources and patient preference. Trial registration number NCT04173624.


  • Peroral endoscopic myotomy and gastroesophageal reflux: A word of caution!

    by Zaheer Nabi, Radhika Chavan, Jahangeer Basha, Anuradha Sekharan, D. Nageshwar Reddy